Lates News

According to the AI quick news, Shanxi Securities issued a research report on March 31, affirming a "buy" rating for iMeike (300896.SZ). The reasons for the rating mainly include: 1) affected by macroeconomic environment and industry competition, the company's revenue for solution and gel products showed varying degrees of decline; 2) independent research and development + extension-based acquisitions enhance the company's industry layout and integration capabilities; 3) acquisitions and subsequent integration of international medical beauty targets accelerate the company's deep integration into the global medical beauty industry chain division of labor and cooperation. (Daily Economic News)